You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD), recommending UCB’s bimekizumab as an option for the treatment of adults with severe plaque psoriasis, a common, chronic immune-mediated systemic disease resulting from sustained inflammation and primarily impacting the skin.